Dimerix to Showcase Phase 3 FSGS Program at Oppenheimer Healthcare Conference

Dimerix Limited ( (AU:DXB) ) has issued an announcement.

Dimerix Limited will present an update on its Phase 3 ACTION3 trial of DMX-200 for FSGS kidney disease at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference in New York and virtually on 27 February 2026. CEO Dr Nina Webster will outline trial recruitment progress by country, planned blinded statistical powering review, commercial partnering status, and broader company growth strategy, underscoring the company’s push to advance a potential first disease-modifying therapy in a rare kidney indication with no approved targeted treatments.

The Phase 3 ACTION3 study is designed as a global, randomised, double-blind, placebo-controlled trial evaluating DMX-200’s impact on proteinuria reduction and kidney function over two years in patients already receiving angiotensin II receptor blockers. Successful results could position Dimerix as a key player in the FSGS treatment landscape, where high unmet need, orphan designations and long patent life create a potentially attractive commercial opportunity for partners and investors.

The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.44 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.

More about Dimerix Limited

Dimerix Limited is an Australian clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases, particularly kidney conditions such as FSGS. Its lead Phase 3 candidate, DMX-200, is a CCR2 antagonist used alongside standard angiotensin II receptor blockers and is supported by a proprietary receptor assay platform and extensive patent protection.

Average Trading Volume: 1,283,257

Technical Sentiment Signal: Hold

Current Market Cap: A$267.2M

For an in-depth examination of DXB stock, go to TipRanks’ Overview page.